UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000042746
Receipt number R000048737
Scientific Title Prospective observational study for the prediction of adverse events of triplet chemotherapy for pancreatic cancer and colorectal cancer by genetic polymorphisms.
Date of disclosure of the study information 2020/12/15
Last modified on 2024/01/12 14:29:05

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prospective observational study for the prediction of adverse events of triplet chemotherapy for pancreatic cancer and colorectal cancer by genetic polymorphisms.

Acronym

The prediction of adverse events of triplet chemotherapy for pancreatic cancer and colorectal cancer by genetic polymorphisms.

Scientific Title

Prospective observational study for the prediction of adverse events of triplet chemotherapy for pancreatic cancer and colorectal cancer by genetic polymorphisms.

Scientific Title:Acronym

The prediction of adverse events of triplet chemotherapy for pancreatic cancer and colorectal cancer by genetic polymorphisms.

Region

Japan


Condition

Condition

pancreatic cancer and colorectal cancer

Classification by specialty

Gastrointestinal surgery Hepato-biliary-pancreatic surgery

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

To analyze the predictors of adverse events of triplet chemotherapy for pancreatic cancer and colorectal cancer by genetic polymorphisms.

Basic objectives2

Others

Basic objectives -Others

The prediction of adverse events

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Search for the predictors of adverse events

Key secondary outcomes

Search for the predictors of therapeutic effects


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients with pancreatic cancer and colorectal cancer (resectable or unresectable)in accordance with the following criteria

1)no gender
2)age over 20 years old
3)the patients who gained written consent by the patient's free will with sufficient understanding after receiving sufficient explanation for the participation of this study
4)the patients who are scheduled to receive or are undergoing any of the following treatments a) to c)
a)triplet chemotherapy (FOLFIRINOX therapy for pancreatic cancer or FOLFOXIRI therapy for colorectal cancer)
b)gemcitabine plus nab-PTX therapy for pancreatic cancer
c)FOLFIRI therapy or FOLFOX therapy for colorectal cancer

Key exclusion criteria

Nothing

Target sample size

150


Research contact person

Name of lead principal investigator

1st name Hiroaki
Middle name
Last name Nagano

Organization

Yamaguchi University Graduate School of Medicine

Division name

Department of Gastroenterological, Breast and Endocrine Surgery

Zip code

755-8505

Address

1-1-1 Minami-Kogushi, Ube, Yamaguchi

TEL

0836-22-2264

Email

hnagano@yamaguchi-u.ac.jp


Public contact

Name of contact person

1st name Gen
Middle name
Last name Kanesada

Organization

Yamaguchi University Graduate School of Medicine

Division name

Department of Gastroenterological, Breast and Endocrine Surgery

Zip code

755-8505

Address

1-1-1 Minami-Kogushi, Ube, Yamaguchi

TEL

0836-22-2264

Homepage URL


Email

gen021eb@yamaguchi-u.ac.jp


Sponsor or person

Institute

Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

Osaka International Cancer Institute

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Center For Clinical Research, Yamaguchi University Hospital

Address

1-1-1 Minami-Kogushi, Ube, Yamaguchi

Tel

0836-22-2428

Email

me223@yamaguchi-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

山口大学大学院 消化器・腫瘍外科学


Other administrative information

Date of disclosure of the study information

2020 Year 12 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2020 Year 11 Month 25 Day

Date of IRB

2020 Year 11 Month 25 Day

Anticipated trial start date

2020 Year 12 Month 21 Day

Last follow-up date

2028 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Adverse events, including neutropenia, are frequently observed in patients undergoing triplet chemotherapy for pancreatic cancer and colorectal cancer. If it becomes possible to analyze the predictors of adverse events by genetic polymorphisms, we believe that it will lead to improvement of therapeutic effect.


Management information

Registered date

2020 Year 12 Month 14 Day

Last modified on

2024 Year 01 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048737


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name